UGT2B17 is a recently identified molecular marker for poor prognosis and drug response in Chronic Lymphocytic Leukemia (CLL), which is the most prevalent adult leukemia subtype in the western world. The goal of this study was to investigate transcriptome changes associated with drug-induced UGT2B17 up-regulation to identify possible upstream regulators of drug response and downstream effects of UGT induction. SOURCE: Chantal Guillemette (chantal.guillemette@crchudequebec.ulaval.ca) - Pharmacogenomics Laboratory Laval University

Pluto Bioinformatics

GSE135030: Treatment of MEC1, EHEB and JVM2 leukemia cell lines with fludarabine, ibrutinib and idelalisib